Cargando…

TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study

BACKGROUND: TP53 and estrogen receptor (ER) both play essential roles in breast cancer development and progression, with recent research revealing cross-talk between TP53 and ER signaling pathways. Although many studies have demonstrated heterogeneity of risk factor associations across ER subtypes,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hurson, Amber N., Abubakar, Mustapha, Hamilton, Alina M., Conway, Kathleen, Hoadley, Katherine A., Love, Michael I., Olshan, Andrew F., Perou, Charles M., Garcia-Closas, Montserrat, Troester, Melissa A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755611/ https://www.ncbi.nlm.nih.gov/pubmed/34737209 http://dx.doi.org/10.1158/1055-9965.EPI-21-0661

Ejemplares similares

Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases
por: Hurson, Amber N., et al.
Publicado: (2022)

Inherited predisposition to breast cancer in the Carolina Breast Cancer Study
por: Walsh, Tom, et al.
Publicado: (2021)

A framework for transcriptome-wide association studies in breast cancer in diverse study populations
por: Bhattacharya, Arjun, et al.
Publicado: (2020)

Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer
por: Patel, Achal, et al.
Publicado: (2022)

TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases
por: Williams, Lindsay A., et al.
Publicado: (2018)

Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study
por: Parada, Humberto, et al.
Publicado: (2017)

Molecular Features of Androgen-Receptor Low, Estrogen Receptor-Negative Breast Cancers in the Carolina Breast Cancer Study
por: Jinna, Nikita, et al.
Publicado: (2023)

Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study
por: Shi, Yifeng, et al.
Publicado: (2023)

Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study
por: Jinna, Nikita D., et al.
Publicado: (2023)

Gene expression patterns associated with p53 status in breast cancer
por: Troester, Melissa A, et al.
Publicado: (2006)

Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study
por: Williams, Lindsay A., et al.
Publicado: (2019)

Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study
por: Chollet-Hinton, Lynn, et al.
Publicado: (2016)

Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay
por: Hurson, Amber N., et al.
Publicado: (2023)

Hepatocyte growth factor pathway expression in breast cancer by race and subtype
por: Jones, Gieira S., et al.
Publicado: (2021)

Parity-related molecular signatures and breast cancer subtypes by estrogen receptor status
por: Rotunno, Melissa, et al.
Publicado: (2014)

Prediction of Toxicant-Specific Gene Expression Signatures after Chemotherapeutic Treatment of Breast Cell Lines
por: Troester, Melissa A., et al.
Publicado: (2004)

RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
por: Walens, Andrea, et al.
Publicado: (2022)

Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features
por: Benefield, Halei C, et al.
Publicado: (2020)

Impact of stromal microenvironment on metabolic phenotypes in breast cancer: evidence for stroma-influenced Warburg effect
por: Brauer, Heather Ann, et al.
Publicado: (2012)

DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival
por: Conway, Kathleen, et al.
Publicado: (2014)

Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer
por: Abubakar, Mustapha, et al.
Publicado: (2021)

Incorporating RNA-based Risk Scores for Genomic Instability to Predict Breast Cancer Recurrence and Immunogenicity in a Diverse Population
por: Hamilton, Alina M., et al.
Publicado: (2023)

Identification of mRNA isoform switching in breast cancer
por: Zhao, Wei, et al.
Publicado: (2016)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

In Vitro and In Vivo Analysis of B-Myb in Basal-Like Breast Cancer
por: Thorner, AR, et al.
Publicado: (2008)

TP53 Status and Response to Treatment in Breast Cancers
por: Varna, Mariana, et al.
Publicado: (2011)

Potential Tumor Suppressor Role for the c-Myb Oncogene in Luminal Breast Cancer
por: Thorner, Aaron R., et al.
Publicado: (2010)

TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer
por: Mukhopadhyay, Utpal K, et al.
Publicado: (2019)

Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression
por: Fassler, Danielle J., et al.
Publicado: (2022)

Germline TP53 mutations in Finnish breast cancer patients
por: Rapakko, K, et al.
Publicado: (2000)

Clinical implications of germline mutations in breast cancer: TP53
por: Schon, Katherine, et al.
Publicado: (2017)

TP53 Mutations Promote Immunogenic Activity in Breast Cancer
por: Liu, Zhixian, et al.
Publicado: (2019)

Impact of TP53 mutations in Triple Negative Breast Cancer
por: Mitri, Zahi I., et al.
Publicado: (2022)

Correction to: TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer
Publicado: (2023)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

A functionally significant SNP in TP53 and breast cancer risk in African-American women
por: Murphy, Maureen E., et al.
Publicado: (2017)

Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals TP53 Aneuploidy–driven Metabolic Reprogramming
por: McClure, Marni B., et al.
Publicado: (2023)

TP53 intron 6 polymorphism and the risk of ovarian and breast cancer.
por: Mavridou, D., et al.
Publicado: (1998)

The R337H mutation in TP53 and breast cancer in Brazil
por: Gomes, Magda CB, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_h7o0ip2isj6om7gi8drs2j2bqu